ProBio Showcases Advanced Solutions at ASGCT 2025 Conference in New Orleans
ProBio Showcases Advanced Solutions at ASGCT 2025 Conference in New Orleans
ProBio, a global leader in contract development and manufacturing, is gearing up for a significant presence at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, scheduled for May 13-15, 2025, in New Orleans, Louisiana. The company has revealed plans to present six innovative poster presentations at this prestigious event, which will highlight their latest advancements in DNA and viral vector manufacturing technologies.
Presentations Overview
The six poster presentations aim to bring attention to ProBio’s cutting-edge developments, particularly in plasmid DNA production, enzymatic linearized DNA for mRNA therapeutics, as well as optimized processes for recombinant adeno-associated virus (rAAV) and lentiviral vector (LVV) manufacturing. Each presentation addresses key challenges within the industry and proposes solutions that could revolutionize therapeutic developments.
Featured Titles and Authors
- - Title: Advanced Plasmid Linearization Using Type I and Type II Restriction Enzymes
Session: Tuesday Poster Reception
Date and Time: May 13, 2025, 6:00 PM–7:30 PM
Location: Poster Hall I2
Authors: Charlie Fan, Justin Chen, Philemon Asfeha, Rui Tang, Pawan Bhatt, Delicia Henriques
- - Title: Enhanced Yield and Structural Integrity in Plasmid Biomanufacturing Employing the PowerS-ITR E. coli Platform
Session: Wednesday Poster Reception
Date and Time: May 14, 2025, 5:30 PM–7:00 PM
Location: Poster Hall I2
Authors: Shrey Amin, Ssempa Kisaalita, Sneha Vilayur, Delicia Henriques, Ryan Rubino, Aparna Nandakumar, Murali Jujjavarapu, Aneri Maniar, Philemon Asfeha, Rui Tang
- - Title: Optimization and Comparative Analysis of Host Cell DNA/RNA Quantification and Plasmid Supercoiled Percentage
Session: Thursday Poster Reception
Date and Time: May 15, 2025, 5:30 PM–7:00 PM
Location: Poster Hall I2
Authors: Delicia Henriques, Murali Jujjavarapu, Aparna Nandakumar, Aneri Maniar, Ryan Rubino, Eric Gliniak, Minqi Jiang, Philemon Asfeha
- - Title: Efficient Viral Vector Production Cell Line — PowerS™-293/293T
Session: Thursday Poster Reception
Date and Time: May 15, 2025, 5:30 PM–7:00 PM
Location: Poster Hall I2
Authors: Chunling Xuan, Xiangyu Zang, Rongna Ding, Jane Liu, Andy Tran, Haibo Zhang, Davis Xie, Eric Lin, Moco Wang
- - Title: Quality by Design in Plasmid DNA and Gene Therapy: ProBio CDMO's Digital QMS for Risk-Based Manufacturing Excellence
Session: Thursday Poster Reception
Date and Time: May 15, 2025, 5:30 PM–7:00 PM
Location: Poster Hall I2
Authors: Julie Erwin, Sham Lasker, Taruj Patel, Ben Chen
- - Title: Enzymatic Linearized DNA – A Novel, Cell-Free Platform for Accelerated mRNA Therapeutic Development
Session: Thursday Poster Reception
Date and Time: May 15, 2025, 5:30 PM–7:00 PM
Location: Poster Hall I2
Authors: Pawan Bhatt, Rui Tang, Luffy Chen, Xiaoyu Qin, Xinmiao Zhang, Cong Li, Alvin Jogasuria, Luffy Chen
Commitment to Innovation
Allen Guo, CEO of ProBio, remarked on their dedication to advancing cell and gene therapy, stating, "Our presence at ASGCT this year demonstrates ProBio's commitment to advancing cell and gene therapy through innovative manufacturing solutions. The presentations highlight our progress in developing efficient, scalable, and high-quality platforms for plasmid DNA and viral vector production to support pre-clinical and clinical program needs." He further emphasized the importance of their state-of-the-art facilities in Hopewell, which contribute significantly to developing therapies that were once thought impossible.
Join ProBio at ASGCT 2025
Attendees are encouraged to visit ProBio at Poster Hall I2 and Booth 1223 to learn more about their innovative solutions. As the company invites innovators, collaborators, and potential partners to join them in shaping the future of gene and cell therapy, this year’s ASGCT meeting promises to be a groundbreaking event in the industry.
About ProBio
ProBio is recognized globally for advancing the development and manufacturing of next-generation biologics and advanced therapies for the biotech and pharmaceutical sectors. Acting as an integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio partners with clients to optimize drug development processes and reduce time-to-market while providing comprehensive lifecycle support. Their flexible licensing and co-development options aim to simplify navigating the complexities of human diseases with next-gen therapeutics. To explore ProBio’s offerings, please visit ProBio's Website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.